LENZ Therapeutics Submits VIZZ Presbyopia Treatment for UK Approval Following EU Validation

Key Takeaways

• LENZ Therapeutics submitted VIZZ (aceclidine 1.44%) to UK MHRA for presbyopia treatment approval
• VIZZ represents the first and only aceclidine-based eye drop specifically designed for presbyopia in adults
• UK submission follows successful EMA validation in March 2026, expanding potential European market access

---

LENZ Therapeutics, Inc. (Nasdaq: LENZ) announced April 20, 2026, that it has submitted a Marketing Authorization Application (MAA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for VIZZ® (aceclidine ophthalmic solution) 1.44%, seeking approval for presbyopia treatment in adults.

The San Diego-based pharmaceutical company’s UK regulatory submission represents a significant milestone in expanding access to what the company describes as the first and only aceclidine-based eye drop specifically developed for presbyopia treatment.

Regulatory Progress Across Europe

The MHRA submission builds on LENZ Therapeutics’ recent regulatory success in Europe, where the European Medicines Agency (EMA) validated the company’s MAA for VIZZ in March 2026. This dual-track regulatory approach positions the company to potentially serve both EU and UK markets simultaneously.

Presbyopia, an age-related vision condition affecting near-sight clarity, impacts millions of adults worldwide. The condition typically begins affecting individuals in their 40s and progressively worsens with age, creating a substantial market opportunity for effective treatments.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications and Timeline

VIZZ’s unique aceclidine-based formulation differentiates it from existing presbyopia treatments in the market. The 1.44% concentration represents a specific therapeutic approach that LENZ has developed through clinical trials and regulatory review processes.

The company’s strategic focus on both EU and UK markets reflects the significant commercial potential for presbyopia treatments in these regions. With aging populations across Europe and the UK, demand for effective presbyopia solutions continues growing.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps in Approval Process

The MHRA will now conduct its comprehensive review of LENZ Therapeutics’ submission, evaluating VIZZ’s safety and efficacy data. This review process typically involves multiple phases of regulatory assessment before final approval decisions.

Success in both EU and UK markets would provide LENZ Therapeutics with substantial commercial opportunities and establish VIZZ as a leading presbyopia treatment option for European patients seeking alternatives to reading glasses or surgical interventions.

---

Frequently Asked Questions

What makes VIZZ different from other presbyopia treatments?

VIZZ is the first and only aceclidine-based eye drop specifically formulated at 1.44% concentration for presbyopia treatment, offering a unique pharmacological approach compared to existing therapies.

When will VIZZ be available to UK patients?

The timeline depends on MHRA’s review process, which typically takes several months to over a year. The company has not provided specific availability dates pending regulatory approval.

How does the UK submission relate to EU approval?

The UK MHRA submission follows EMA validation in March 2026, representing parallel regulatory pathways that could enable VIZZ access across both EU and UK markets upon respective approvals.

Related coverage

• Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
• Vabysmo gains EU approval for retinal vein occlusion: what changes next
• GSK Blenrep wins FDA approval in relapsed multiple myeloma